Y Intercept (Hong Kong) LTD Argenx Se Transaction History

Y Intercept (Hong Kong) LTD

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $5.67 Million - $7.19 Million	15,927 New	15,927 $6.85 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $1.24 Million - $1.85 Million	3,365 New	3,365 $1.65 Million
Q1 2023 May 09, 2023	BUY	$334.23 - $403.65 $527,414 - $636,959	1,578 New	1,578 $587,000
Q2 2022 Aug 08, 2022	BUY	$269.58 - $378.88 $657,775 - $924,467	2,440 New	2,440 $924,000
Q1 2022 May 16, 2022	SELL	$254.45 - $351.06 $396,178 - $546,600	-1,557 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $423,519 - $549,667	1,557 New	1,557 $545,000
Q3 2021 Nov 15, 2021	SELL	$295.0 - $350.58 $555,485 - $660,142	-1,883 Closed	0 $0
Q2 2021 Aug 26, 2021	BUY	$257.11 - $319.92 $484,138 - $602,409	1,883 New	1,883 $567,000
Q2 2021 Aug 12, 2021	SELL	$257.11 - $319.92 $610,636 - $759,810	-2,375 Closed	0 $567,000
Q1 2021 May 12, 2021	BUY	$268.3 - $380.31 $637,212 - $903,236	2,375 New	2,375 $647,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.